Drugs / KSX01-TCRT
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06150365 | Nov 2023 → Dec 2026 expected | neoplastic disease or syndrome | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 0 | NCT05811975 | Mar 2023 → Dec 2026 expected | T-cell Subgroups, non-HLA-linked, refractory malignant neoplasm | TCRx Therapeutics Co.Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSX01-TCRT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05811975 ↗ |
| Modality | Cell therapy | “TCR-T cell injection” NCT05811975 ↗ |